본문 바로가기
  • Home

Integrated in vivo cardiac safety evaluation using systemic pharmacology technique

  • Journal of Alternatives to Animal Experiments
  • Abbr : J Altern Anim Exp
  • 2018, 12(1), pp.1-8
  • DOI : 10.23032/jaae.2018.12.1.002
  • Publisher : Korean Society for Alternatives to Animal Experiments
  • Research Area : Medicine and Pharmacy > Veterinary > Basic Veterinary Medicine > Laboratory Animal Medicine
  • Received : December 18, 2018
  • Accepted : December 27, 2018
  • Published : December 29, 2018

Kun-Hee Oh 1 Ki-Suk Kim 2 Hyang-Ae Lee 2 Seung-Hoon Han 1 Dong-Seok Yim 1

1가톨릭대학교 의과대학 계량약리학연구소
2한국화학연구원 부설 안전성평가연구소 차세대의약평가연구단

ABSTRACT

ICH S7B and E14 guidelines, which were first released in 2005, are focused on hERG blockade and QT prolongation by drugs. However, cumulated evidences on some pitfalls of the guidelines resulted in the initiation of the comprehensive in vitro proarrhythmia assay (CiPA) project. Results of the CiPA are expected to change global regulatory environment on the cardiac safety of drugs. In this study, we reproduced two components of the CiPA to assess the performance of their in silico biomarker using in vitro ion channel assay data. The process to obtain qNET, a biomarker proposed by CiPA, was fully reproduced through in vitro and in silico studies in selected three drugs (verapamil, ranolazine, moxifloxacin). Throughout the reproducing research, we obtained many practical experiences not included in publications by the CiPA. For further understanding of this new regulatory paradigm, clinical ECG in human and another in silico method are to be performed.

Citation status

* References for papers published after 2022 are currently being built.